Biosimilar of Xolair shows Similarity in Reducing Asthma Exacerbations
Pharmacy Times,
Investigators found that P043 (Zerafil; CinnaGen), a biosimilar of omalizumab (Xolair; Genentech, Novartis), was equivalent to…
Investigators found that P043 (Zerafil; CinnaGen), a biosimilar of omalizumab (Xolair; Genentech, Novartis), was equivalent to…
Credit: Adobe Stock P043, anomalizumab biosimilar, was found to be equivalent to reference omalizumab in reducing exacerbations…